- Home
- ZNTL vs NEWT Comparison
ZNTL vs NEWT Comparison
Compare ZNTL & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- NEWT
- Stock Information
- Founded
- ZNTL 2014
- NEWT 1998
- Country
- ZNTL United States
- NEWT United States
- Employees
- ZNTL N/A
- NEWT N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- ZNTL Health Care
- NEWT Finance
- Exchange
- ZNTL Nasdaq
- NEWT Nasdaq
- Market Cap
- ZNTL 118.3M
- NEWT 316.7M
- IPO Year
- ZNTL 2020
- NEWT N/A
- Fundamental
- Price
- ZNTL $1.72
- NEWT $10.99
- Analyst Decision
- ZNTL Buy
- NEWT Hold
- Analyst Count
- ZNTL 6
- NEWT 4
- Target Price
- ZNTL $6.53
- NEWT $13.25
- AVG Volume (30 Days)
- ZNTL 688.6K
- NEWT 227.8K
- Earning Date
- ZNTL 11-11-2025
- NEWT 10-29-2025
- Dividend Yield
- ZNTL N/A
- NEWT 6.88%
- EPS Growth
- ZNTL N/A
- NEWT 21.23
- EPS
- ZNTL N/A
- NEWT 2.01
- Revenue
- ZNTL $26,865,000.00
- NEWT $364,004,000.00
- Revenue This Year
- ZNTL N/A
- NEWT N/A
- Revenue Next Year
- ZNTL N/A
- NEWT $12.40
- P/E Ratio
- ZNTL N/A
- NEWT $5.46
- Revenue Growth
- ZNTL N/A
- NEWT 20.91
- 52 Week Low
- ZNTL $1.01
- NEWT $9.12
- 52 Week High
- ZNTL $4.44
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- ZNTL 57.94
- NEWT 45.68
- Support Level
- ZNTL $1.49
- NEWT $10.30
- Resistance Level
- ZNTL $1.67
- NEWT $11.20
- Average True Range (ATR)
- ZNTL 0.11
- NEWT 0.32
- MACD
- ZNTL 0.01
- NEWT 0.04
- Stochastic Oscillator
- ZNTL 65.71
- NEWT 65.15
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.